Psoriatic Arthritis Treatment Guideline

Psoriatic Arthritis Treatment GUIDELINES Pocket Guide

Approved By

American College of Rheumatology

Digital Subscription $4.99 Add to Cart
Print $9.95 Add to Cart
Free Sample

The digital subscription version of the Psoriatic Arthritis Treatment GUIDELINES Pocket Guide contains all the same great information found in the physical pocket guide, and can be accessed on mobile devices and online:

  • Price: $4.99 per year
    • Subscribe to additional guideline titles for discounted rates
  • Includes automatic updates during the term of your subscription
  • CPT® and ICD10 codes can be added to certain guidelines for an additional fee
  • Supported platforms
    • iPhone and iPad
    • Android phones and tablets
    • Online (internet connection required)
  • Content on the Guideline Central mobile app accessible without an internet connection
    • Access to additional guideline summaries, clinical calculators, and more

For mobile access, download the free app from the App Store or Google Play and use the same email address and password as the website to login.

For individual use only; contact us for group and site licenses.

The Psoriatic Arthritis GUIDELINES® Pocket Guide is based on the latest guidelines of the American College of Rheumatology and was developed with their collaboration. It contains severity definitions, graded recommendations for the management of patients with psoriatic arthritis at all levels of treatment and four algorithms. It includes both pharmacologic and nonpharmacologic treatment modalities.

  • Spiral-bound
  • 24 Pages
  • 80# Diamond Silk Cover with Satin Aqueous Coating
  • 4.25″ x 7.25″
  • Notes and Definitions
  • Figures:
    • Pharmacologic, Nonpharmacologic, and Symptomatic Therapies for PsA
    • Examples of “Severe” PsA and Psoriasis
  • Algorithms
    • Patients with Active PsA Who are Treatment-Naïve (no exposure to OSMs)
    • Patients with Active PsA Despite Treatment
  • With OSMs
    • Patients with Active PsA Despite Treatment With a TNFi as Monotherapy or as Combination Therapy with MTX
    • Patients with Active PsA Despite Treatment With IL-17i or IL-12/23i Biologic Monotherapy
  • Tables
    • Recommendations for the Initial Treatment of Patients With Active PsA Who Are OSM- and Other Treatment-Naïve
    • Recommendations for Treatment of Patients With Active PsA Despite Treatment With an OSM
    • Recommendations for Treatment of Patients With Active PsA Despite Treatment With a TNFi Biologic, as Monotherapy or in Combination with MTX
    • Recommendations for Treatment of Patients With Active PsA Despite Treatment With an IL-17i or an IL-12/23i Biologic Monotherapy
    • Recommendations for Treatment of Patients With Active PsA Including Treat-To-Target, Active Axial Disease, Enthesitis, or Active IBD
    • Recommendations for Treatment of Patients With Active PsA and Comorbidities, Including Concomitant Diabetes and Recurrent Serious Infections
    • Recommendations for Vaccination in Patients With Active PsA
    • Recommendations for Treatment of Patients With Active PsA With Nonpharmacologic Interventions

The American College of Rheumatology's mission is advancing rheumatology! The organization represents over 9,400 rheumatologists and rheumatology health professionals around the world. The ACR offers its members the support they need to ensure that they are able to continue their innovative work by providing programs of education, research, advocacy, and practice support.

  • Guideline Pricing

  • Single Title
    $4.99 / year
  • Any 5 Titles
    $23.99 / year
  • Any 10 Titles
    $41.99 / year
  • Any 35 Titles
    $74.99 / year
  • All Available Titles
    $169.99 / year

To get started, log in or create your free account Create Account